Arranon
nelarabine
- Strength
- 5 mg/mL
- Form
- Injection
- Class
- Nucleoside Metabolic Inhibitor
Novartis Pharmaceuticals Corporation
Not stocked by us — reference only
Listed by Gland Pharma Limited
| Dosage form | Injection |
|---|---|
| Route | Intravenous |
| Drug class | Nucleoside Metabolic Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 68083-233 |
| FDA application | ANDA212605 |
| RxNorm concept | 603566 |
| Package sizes listed | 1 |
| Marketed since | January 2024 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
nelarabine
Novartis Pharmaceuticals Corporation
Not stocked by us — reference only
nelarabine
Sandoz Inc
Not stocked by us — reference only
XGen Pharmaceuticals DJB, Inc.
Not stocked by us — reference only
Zydus Pharmaceuticals USA Inc.
Not stocked by us — reference only
Shorla Oncology Inc.
Not stocked by us — reference only
Shorla Oncology Inc.
Not stocked by us — reference only
Sagent Pharmaceuticals
Not stocked by us — reference only
Alembic Pharmaceuticals Limited
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.